NO985574D0 - FremgangsmÕter og preparater anvendelige for inhibering av angiogenese - Google Patents

FremgangsmÕter og preparater anvendelige for inhibering av angiogenese

Info

Publication number
NO985574D0
NO985574D0 NO985574A NO985574A NO985574D0 NO 985574 D0 NO985574 D0 NO 985574D0 NO 985574 A NO985574 A NO 985574A NO 985574 A NO985574 A NO 985574A NO 985574 D0 NO985574 D0 NO 985574D0
Authority
NO
Norway
Prior art keywords
alpha
beta
growth factor
inhibiting angiogenesis
methods
Prior art date
Application number
NO985574A
Other languages
English (en)
Other versions
NO985574L (no
Inventor
Peter Brooks
David A Cheresh
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO985574D0 publication Critical patent/NO985574D0/no
Publication of NO985574L publication Critical patent/NO985574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO985574A 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av angiogenese NO985574L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1586996P 1996-05-31 1996-05-31
US1873396P 1996-05-31 1996-05-31
PCT/US1997/009158 WO1997045137A1 (en) 1996-05-31 1997-05-30 Methods and compositions useful for inhibition of angiogenesis

Publications (2)

Publication Number Publication Date
NO985574D0 true NO985574D0 (no) 1998-11-27
NO985574L NO985574L (no) 1999-02-01

Family

ID=26687899

Family Applications (2)

Application Number Title Priority Date Filing Date
NO985574A NO985574L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO985575A NO985575L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO985575A NO985575L (no) 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Country Status (14)

Country Link
EP (2) EP0951295B1 (no)
JP (1) JP2002515036A (no)
KR (2) KR20000016301A (no)
CN (1) CN1226254A (no)
AT (1) ATE470450T1 (no)
BR (1) BR9709514A (no)
CA (2) CA2256543C (no)
CZ (2) CZ380098A3 (no)
DE (1) DE69739907D1 (no)
DK (1) DK0951295T3 (no)
HU (2) HUP9902099A3 (no)
NO (2) NO985574L (no)
PL (2) PL330240A1 (no)
WO (2) WO1997045447A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
DE69927380T2 (de) 1998-07-14 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Oxazolidinone zur behandlung von augeninfektionen
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6344484B1 (en) 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
EP1285001A1 (en) * 2000-05-26 2003-02-26 Glaxo Group Limited Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof
CN1329167A (zh) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人非整合蛋白－金属蛋白酶10.67和编码这种多肽的多核苷酸
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
ATE415163T1 (de) 2000-11-01 2008-12-15 Merck Patent Gmbh Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US7019108B2 (en) * 2001-06-01 2006-03-28 University Of Southern California Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
AU2002319282B2 (en) * 2001-08-01 2007-06-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
FR2856598B1 (fr) * 2003-06-25 2005-10-28 Inst Nat Sante Rech Med Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP1862541A1 (en) * 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
US20110243927A1 (en) * 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
MX346362B (es) 2009-11-10 2017-03-15 Allegro Pharmaceuticals Inc * Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
JP6428604B2 (ja) 2013-04-04 2018-11-28 味の素株式会社 脱保護方法
EP3191519A1 (en) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
CN111748041B (zh) * 2019-03-11 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 微环境控释型功能化水凝胶、其制备方法及应用
CN116239704B (zh) * 2023-05-09 2023-07-14 北京青云智创科技有限公司 一种治疗新生血管性眼病的多肽及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
ATE308981T1 (de) * 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
WO1997045137A8 (en) 2001-02-01
EP0907661A1 (en) 1999-04-14
EP0951295A1 (en) 1999-10-27
EP0907661A4 (en) 2000-07-26
HUP9902099A2 (hu) 1999-09-28
WO1997045137A1 (en) 1997-12-04
CN1226254A (zh) 1999-08-18
HUP9901628A3 (en) 2002-11-28
NO985575D0 (no) 1998-11-27
BR9709514A (pt) 1999-08-10
CZ380098A3 (cs) 1999-05-12
KR20000016301A (ko) 2000-03-25
CA2256543C (en) 2010-12-07
CA2256543A1 (en) 1997-12-04
NO985575L (no) 1999-02-01
JP2002515036A (ja) 2002-05-21
HUP9901628A2 (hu) 1999-08-30
ATE470450T1 (de) 2010-06-15
DK0951295T3 (da) 2010-09-13
NO985574L (no) 1999-02-01
WO1997045447A1 (en) 1997-12-04
PL330241A1 (en) 1999-05-10
HUP9902099A3 (en) 2001-10-29
CZ383498A3 (cs) 1999-05-12
DE69739907D1 (de) 2010-07-22
KR20000016302A (ko) 2000-03-25
PL330240A1 (en) 1999-05-10
CA2256588A1 (en) 1997-12-04
EP0951295B1 (en) 2010-06-09
EP0951295A4 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
NO985574D0 (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO980622D0 (no) Fremgangsmåte og preparater anvendelige for inhibering av &lt;alfa&gt;v&lt;beta&gt;5-formidlet angiogenese
MX9604145A (es) Metodos y composiciones utiles para la inhibicion de angiogenesis.
EP0752987A4 (en) PYRIMIDINE DERIVATIVES AS INTERLEUKIN INHIBITORS
TW369521B (en) Androstenone derivative
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EP1034164A4 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
IL93508A0 (en) Novel benzimidazole and azabenimidazole derivatives,their methods of preparation,synthesis intermediates and pharmaceutical compositions in which they are present and which are useful especially for the treatment of cardiovascular diseases and duodenal ulcers
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
ATE389655T1 (de) Pyrimidinderivate
DE69726281D1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
ITRM920408A0 (it) Colture di tessuto di mucosa congiuntivale differenziata, procedimentoper la loro preparazione e supporti per il loro uso.
IT1251497B (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
IT1243734B (it) Composizione per uso terapeutico e/o cosmetico per il trattamento di disturbi circolatori e per trattamenti di medicina estetica
DE69121210D1 (de) Therapeutische verwendung des fibroblastenwachstumsfaktors
MA23755A1 (fr) Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires
IT218963Z2 (it) Struttura di muretto artificiale, opportunamente attrezzato, particolarmente per l&#39;arredamento di giardini, parchi e terrazzi
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
FR2745719B1 (fr) Composition pour le traitement d&#39;affections cutanees
ITMI910173A1 (it) Gancio regolabile per l&#39;appendimento e l&#39;assestamento di mobili pensili
ITFI920120A1 (it) Uso dell&#39;eparansolfato per il trattamento di prostatiti ed emorroidi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application